The Super Bowl of Stents
Get ready for the next drug-coated stent showdown, which starts Sunday at the annual American College of Cardiology conference in Orlando, Fla.
Another big attraction features research comparing Medtronic's (MDT) experimental Endeavor drug-coated stent with an uncoated Medtronic stent.
The stakes are big for all three companies. J&J hopes a company-financed study will help convince cardiologists to switch to Cypher from Taxus, which entered the market in March 2004, 11 months after Cypher.Boston Scientific has shrugged off a stent recall this summer to retain its dominant position. The companies don't agree on market-share figures, but roughly speaking, Taxus has about a 2-to-1 edge. Medtronic is hoping that its Endeavor test will provide enough compelling information to gain an accelerated review by the Food and Drug Administration. To many analysts, these results will indicate whether the company's stent enters the U.S. market in 2006 or 2007. Every minute counts because Guidant (GDT), which is being acquired by J&J, and Abbott Laboratories (ABT) also are working on drug-coated stents. Drug-coated stents are meshlike metal tubes inserted into arteries after vessel-clogging plaque has been removed. The stents facilitate blood flow and reduce the risk of heart attack. The drug-coated stents, also known as drug-eluting stents, release chemicals into the arteries periodically to reduce the risk of arteries reclogging. Uncoated stents reduce the reclogging risk, too, but the drug-coated devices do a better job. The Cypher versus Taxus performance will be unveiled via a J&J-sponsored test nicknamed Reality. "Even if the data revealed slightly more favorable, non-significant trends for Cypher, the difference ... is likely not enough to induce a material shift away from Taxus use," said a recent research report from Goldman Sachs. And if Cypher's results appeared slightly better, "Taxus use is likely to be dictated more so by the delivery/flexibility" of the Taxus delivery system.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV